title: Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression.
abstract: BACKGROUND
  Sleep effects of antidepressants are important clinically and for elucidating mechanism of action: selective serotonin reuptake inhibitors disturb sleep and 5-HT(2) receptor-blocking compounds may enhance sleep quality.
  
  
  OBJECTIVE
  To compare the objective and subjective effects on sleep of paroxetine and nefazodone in patients with moderate to severe depression.
  
  
  METHODS
  Forty patients with depression were randomised to take paroxetine 20-40 mg/day or nefazodone 400-600 mg/day for 8 weeks. Objective and subjective quality of sleep and depression measures were assessed throughout.
  
  
  RESULTS
  Nefazodone significantly increased objective sleep efficiency and total sleep time, and improved subjective sleep on days 3 and 10. Paroxetine decreased sleep efficiency early in treatment and some sleep disruption remained at week 8. Paroxetine but not nefazodone produced marked suppression of rapid eye movement (REM) sleep.
  
  
  CONCLUSIONS
  Nefazodone improves sleep in early treatment compared with paroxetine in patients with moderate to severe depression. These effects are seen within the first 2 weeks of treatment and diminish thereafter.
authors.affiliation: Psychopharmacology Unit, University of Bristol, UK.
authors.forename: J A
authors.initials: JA
authors.lastname: Hicks
authors.forename: S V
authors.initials: SV
authors.lastname: Argyropoulos
authors.forename: A S
authors.initials: AS
authors.lastname: Rich
authors.forename: J R
authors.initials: JR
authors.lastname: Nash
authors.forename: C J
authors.initials: CJ
authors.lastname: Bell
authors.forename: C
authors.initials: C
authors.lastname: Edwards
authors.forename: D J
authors.initials: DJ
authors.lastname: Nutt
authors.forename: S J
authors.initials: SJ
authors.lastname: Wilson
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D017374:Paroxetine / Q000627:therapeutic use*; D010879:Piperazines; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012890:Sleep / Q000187:drug effects*; D012895:Sleep, REM / Q000187:drug effects; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D017374:Paroxetine; D010879:Piperazines; D017367:Selective Serotonin Reuptake Inhibitors; D014230:Triazoles; C051752:nefazodone